These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 34526011)

  • 1. The effect of additional antimicrobial therapy on the outcomes of patients with idiopathic pulmonary fibrosis: a systematic review and meta-analysis.
    Chen CY; Chen CH; Wang CY; Lai CC; Chao CM; Wei YF
    Respir Res; 2021 Sep; 22(1):243. PubMed ID: 34526011
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treating idiopathic pulmonary fibrosis with the addition of co-trimoxazole: a randomised controlled trial.
    Shulgina L; Cahn AP; Chilvers ER; Parfrey H; Clark AB; Wilson EC; Twentyman OP; Davison AG; Curtin JJ; Crawford MB; Wilson AM
    Thorax; 2013 Feb; 68(2):155-62. PubMed ID: 23143842
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of Antimicrobial Therapy on Respiratory Hospitalization or Death in Adults With Idiopathic Pulmonary Fibrosis: The CleanUP-IPF Randomized Clinical Trial.
    Martinez FJ; Yow E; Flaherty KR; Snyder LD; Durheim MT; Wisniewski SR; Sciurba FC; Raghu G; Brooks MM; Kim DY; Dilling DF; Criner GJ; Kim H; Belloli EA; Nambiar AM; Scholand MB; Anstrom KJ; Noth I;
    JAMA; 2021 May; 325(18):1841-1851. PubMed ID: 33974018
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design and rationale of a multi-center, pragmatic, open-label randomized trial of antimicrobial therapy - the study of clinical efficacy of antimicrobial therapy strategy using pragmatic design in Idiopathic Pulmonary Fibrosis (CleanUP-IPF) clinical trial.
    Anstrom KJ; Noth I; Flaherty KR; Edwards RH; Albright J; Baucom A; Brooks M; Clark AB; Clausen ES; Durheim MT; Kim DY; Kirchner J; Oldham JM; Snyder LD; Wilson AM; Wisniewski SR; Yow E; Martinez FJ;
    Respir Res; 2020 Mar; 21(1):68. PubMed ID: 32164673
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Efficacy and Mechanism Evaluation of Treating Idiopathic Pulmonary fibrosis with the Addition of Co-trimoxazole (EME-TIPAC): study protocol for a randomised controlled trial.
    Hammond M; Clark AB; Cahn AP; Chilvers ER; Fraser WD; Livermore DM; Maher TM; Parfrey H; Swart AM; Stirling S; Thickett D; Whyte M; Wilson A
    Trials; 2018 Feb; 19(1):89. PubMed ID: 29402332
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acute Exacerbation and Decline in Forced Vital Capacity Are Associated with Increased Mortality in Idiopathic Pulmonary Fibrosis.
    Paterniti MO; Bi Y; Rekić D; Wang Y; Karimi-Shah BA; Chowdhury BA
    Ann Am Thorac Soc; 2017 Sep; 14(9):1395-1402. PubMed ID: 28388260
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-life experiences in a single center: efficacy of pirfenidone in idiopathic pulmonary fibrosis and fibrotic idiopathic non-specific interstitial pneumonia patients.
    Feng H; Zhao Y; Li Z; Kang J
    Ther Adv Respir Dis; 2020; 14():1753466620963015. PubMed ID: 33070705
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of Recombinant Human Pentraxin 2 vs Placebo on Change in Forced Vital Capacity in Patients With Idiopathic Pulmonary Fibrosis: A Randomized Clinical Trial.
    Raghu G; van den Blink B; Hamblin MJ; Brown AW; Golden JA; Ho LA; Wijsenbeek MS; Vasakova M; Pesci A; Antin-Ozerkis DE; Meyer KC; Kreuter M; Santin-Janin H; Mulder GJ; Bartholmai B; Gupta R; Richeldi L
    JAMA; 2018 Jun; 319(22):2299-2307. PubMed ID: 29800034
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pirfenidone in patients with idiopathic pulmonary fibrosis and more advanced lung function impairment.
    Nathan SD; Costabel U; Albera C; Behr J; Wuyts WA; Kirchgaessler KU; Stauffer JL; Morgenthien E; Chou W; Limb SL; Noble PW
    Respir Med; 2019 Jul; 153():44-51. PubMed ID: 31153107
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of Co-trimoxazole (Trimethoprim-Sulfamethoxazole) vs Placebo on Death, Lung Transplant, or Hospital Admission in Patients With Moderate and Severe Idiopathic Pulmonary Fibrosis: The EME-TIPAC Randomized Clinical Trial.
    Wilson AM; Clark AB; Cahn T; Chilvers ER; Fraser W; Hammond M; Livermore DM; Maher TM; Parfrey H; Swart AM; Stirling S; Thickett DR; Whyte M;
    JAMA; 2020 Dec; 324(22):2282-2291. PubMed ID: 33289822
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Longitudinal clinical outcomes in a real-world population of patients with idiopathic pulmonary fibrosis: the PROOF registry.
    Wuyts WA; Dahlqvist C; Slabbynck H; Schlesser M; Gusbin N; Compere C; Maddens S; Lee YC; Kirchgaessler KU; Bartley K; Bondue B
    Respir Res; 2019 Oct; 20(1):231. PubMed ID: 31651324
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and tolerability of acetylcysteine and pirfenidone combination therapy in idiopathic pulmonary fibrosis: a randomised, double-blind, placebo-controlled, phase 2 trial.
    Behr J; Bendstrup E; Crestani B; Günther A; Olschewski H; Sköld CM; Wells A; Wuyts W; Koschel D; Kreuter M; Wallaert B; Lin CY; Beck J; Albera C
    Lancet Respir Med; 2016 Jun; 4(6):445-53. PubMed ID: 27161257
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and adverse events of pirfenidone in treating idiopathic pulmonary fibrosis.
    Ren H; Wang K; Yang H; Gao L
    Saudi Med J; 2017 Sep; 38(9):889-894. PubMed ID: 28889145
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of N-Acetylcysteine in Idiopathic Pulmonary Fibrosis: A Systematic Review and Meta-Analysis.
    Sun T; Liu J; Zhao W
    Medicine (Baltimore); 2016 May; 95(19):e3629. PubMed ID: 27175674
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of lung function and survival in RECAP: An open-label extension study of pirfenidone in patients with idiopathic pulmonary fibrosis.
    Costabel U; Albera C; Bradford WZ; Hormel P; King TE; Noble PW; Sahn SA; Valeyre D; du Bois RM
    Sarcoidosis Vasc Diffuse Lung Dis; 2014 Oct; 31(3):198-205. PubMed ID: 25363219
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Clinical Efficacy of Pulmonary Hypertension-Specific Agents in Idiopathic Pulmonary Fibrosis: Systematic Review and Meta-Analysis of Randomized Controlled Clinical Trials.
    Lee J; Song JU
    J Korean Med Sci; 2020 Mar; 35(8):e48. PubMed ID: 32103644
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cyclophosphamide for connective tissue disease-associated interstitial lung disease.
    Barnes H; Holland AE; Westall GP; Goh NS; Glaspole IN
    Cochrane Database Syst Rev; 2018 Jan; 1(1):CD010908. PubMed ID: 29297205
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy, safety, and tolerability of combined pirfenidone and N-acetylcysteine therapy: a systematic review and meta-analysis.
    Shi H; Yin D; Bonella F; Kreuter M; Oltmanns U; Li X; Peng S; Wei L
    BMC Pulm Med; 2020 May; 20(1):128. PubMed ID: 32380989
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Baseline characteristics and survival of patients of idiopathic pulmonary fibrosis: a longitudinal analysis of the Swedish IPF Registry.
    Gao J; Kalafatis D; Carlson L; Pesonen IHA; Li CX; Wheelock Å; Magnusson JM; Sköld CM
    Respir Res; 2021 Feb; 22(1):40. PubMed ID: 33546682
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.